Frédéric Bibeau

<i>KRAS</i> Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

Astrid Lièvre, Jean‐Baptiste Bachet, Valérie Boige et al. · Journal of Clinical Oncology · 2008 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA

Alain R. Thierry, Florent Moulière, Safia El Messaoudi et al. · Nature Medicine · 2014 · 685 citations

Medicine, Molecular Genetics, Oncology +16

Analysis of <i>PTEN</i> , <i>BRAF</i> , and <i>EGFR</i> Status in Determining Benefit From Cetuximab Therapy in Wild-Type <i>KRAS</i> Metastatic Colon Cancer

Pierre Laurent‐Puig, Anne Cayre, Gilles Manceau et al. · Journal of Clinical Oncology · 2009 · 665 citations

Medicine, Oncology, Pharmacology +17

A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer

Pierre Farmer, Hervé Bonnefoi, Pascale Anderle et al. · Nature Medicine · 2009 · 616 citations · Full text

Medicine, Molecular Biology, Oncology +16

Impact of FcγRIIa-FcγRIIIa Polymorphisms and <i>KRAS</i> Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

Frédéric Bibeau, Evelyne Lopez‐Crapez, Frédéric FIORE et al. · Journal of Clinical Oncology · 2009 · 512 citations

Medicine, Oncology, Pharmacology +16